Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced successful results, dramatically limiting tumor growth and decreasing tumor mass. Designed specifically for ovarian cancers that are resistant to traditional therapies, the new radiopharmaceutical can be produced in 25 minutes at low cost, which leads to better efficiency compared with alternative methods. This research was presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.